LeMaitre Vascular, Inc.(LMAT)Earnings, Financials & Key RatiosLeMaitre Vascular, Inc. (LMAT) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
while the company exhibits strong operational discipline and consistent cash generation, the current P/E TTM of 37.96 suggests that much of the growth potential is already priced into the valuation.
LeMaitre Vascular, Inc. (LMAT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
LeMaitre Vascular, Inc. (LMAT) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.68vs $0.66+3.0% | $67Mvs $67M-0.2% |
| Q1 2026 | Feb 25, 2026 | $0.68vs $0.67+1.5% | $64Mvs $63M+2.6% |
| Q4 2025 | Nov 6, 2025 | $0.62vs $0.56+9.9% | $61Mvs $62M-1.8% |
| Q3 2025 | Aug 5, 2025 | $0.60vs $0.57+5.3% | $64Mvs $61M+5.5% |
Recent stock market news and headlines for LeMaitre Vascular, Inc. (LMAT)
I don't love valuation models because they rely on assumptions, and assumptions can be dangerous. But we still need to pay attention. I sold my position in BIPC not because I don't like the stock or that I'm spooked by recent movement, but rather in the optic of portfolio simplification. Since I started this portfolio in September 2017, I have received a total of $36,444.54 CAD in dividends.
Key metrics vs top competitors for LeMaitre Vascular, Inc. (LMAT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $103.72 | $2.36B | 41.16 | 13.53% | 23.13% | 15.8% | 0.76% | |
| $32.39 | $1.64B | -134.96 | 14.88% | -0.83% | -0.95% | — | |
| $17.32 | $1.97B | -14.20 | 8.28% | -25.66% | -50.82% | — | |
| $12.98 | $536.32M | -15.64 | -3.76% | -10% | -17.65% | — | |
| $35.11 | $1.08B | 23.25 | 5.16% | 4% | 5.4% | — | |
| $71.45 | $4.26B | 33.54 | 11.66% | 9.03% | 8.95% | — |
LeMaitre Vascular, Inc. (LMAT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
LeMaitre Vascular, Inc. (LMAT) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 5, 2026·SEC
Apr 14, 2026·SEC
Feb 25, 2026·SEC
Get notified when LMAT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
LeMaitre Vascular, Inc. (LMAT) stock FAQ — growth, dividends, profitability & financials explained
LeMaitre Vascular, Inc. (LMAT) reported $256.3M in revenue for fiscal year 2025. This represents a 879% increase from $26.2M in 2004.
LeMaitre Vascular, Inc. (LMAT) grew revenue by 13.5% over the past year. This is steady growth.
Yes, LeMaitre Vascular, Inc. (LMAT) is profitable, generating $62.4M in net income for fiscal year 2025 (23.1% net margin).
Yes, LeMaitre Vascular, Inc. (LMAT) pays a dividend with a yield of 0.76%. This makes it attractive for income-focused investors.
LeMaitre Vascular, Inc. (LMAT) has a return on equity (ROE) of 15.8%. This is reasonable for most industries.
LeMaitre Vascular, Inc. (LMAT) generated $79.1M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
